Search Results - "Bolognese, M A"

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates by Miller, P. D, Pannacciulli, N, Brown, J. P, Czerwinski, E, Nedergaard, B. S, Bolognese, M. A, Malouf, J, Bone, H. G, Reginster, J.-Y, Singer, A, Wang, C, Wagman, R. B, Cummings, S. R

“…Context: Denosumab and zoledronic acid (ZOL) are parenteral treatments for patients with osteoporosis. Objective: The objective of the study was to compare the…”
Get full text

Cinacalcet HCl Reduces Hypercalcemia in Primary Hyperparathyroidism across a Wide Spectrum of Disease Severity by Peacock, Munro, Bilezikian, J. P, Bolognese, M. A, Borofsky, Michael, Scumpia, Simona, Sterling, L. R, Cheng, Sunfa, Shoback, Dolores

“…Context: Primary hyperparathyroidism (PHPT) is characterized by elevated serum calcium (Ca) and increased PTH concentrations. Objective: The objective of the…”
Get full text

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial by McClung, M. R., Lewiecki, E. M., Geller, M. L., Bolognese, M. A., Peacock, M., Weinstein, R. L., Ding, B., Rockabrand, E., Wagman, R. B., Miller, P. D.

“…Summary In a phase 2 study, continued denosumab treatment for up to 8 years was associated with continued gains in bone mineral density and persistent…”
Get full text

Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate by Brown, J. P., Roux, C., Ho, P. R., Bolognese, M. A., Hall, J., Bone, H. G., Bonnick, S., van den Bergh, J. P., Ferreira, I., Dakin, P., Wagman, R. B., Recknor, C.

“…Summary Managing osteoporotic patients suboptimally adherent to bisphosphonates (BPs) is difficult. Such patients who remained at higher risk for fracture (≥1…”
Get full text

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis by Brown, J P, Kendler, D L, McClung, M R, Emkey, R D, Adachi, J D, Bolognese, M A, Li, Z, Balske, A, Lindsay, R

“…This study evaluated the efficacy and tolerability of risedronate once a week (35 mg and 50 mg) compared with risedronate 5 mg once daily in women with…”
Get full text

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet by McClung, M. R., Miller, P. D., Brown, J. P., Zanchetta, J., Bolognese, M. A., Benhamou, C. L., Balske, A., Burgio, D. E., Sarley, J., McCullough, L. K., Recker, R. R.

“…Summary Dosing regimens of oral bisphosphonates are inconvenient and contribute to poor compliance. The bone mineral density response to a once weekly…”
Get full text

Cinacalcet HCl Reduces Hypercalcemia in Primary Hyperparathyroidism across a Wide Spectrum of Disease Severity by Peacock, Munro, Bilezikian, J. P, Bolognese, M. A, Borofsky, Michael, Scumpia, Simona, Sterling, Lulu Ren, Cheng, Sunfa, Shoback, Dolores

“…J Clin Endocrinol Metab, 10.1210/jc.2010-1221…”
Get full text

A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab by McClung, M. R., Bolognese, M. A., Brown, J. P., Reginster, J.-Y., Langdahl, B. L., Maddox, J., Shi, Y., Rojeski, M., Meisner, P. D., Grauer, A.

“…Summary This phase 2 study evaluated the efficacy and safety of transitioning to zoledronate following romosozumab treatment in postmenopausal women with low…”
Get full text

Hyptis pectinata essential oil: chemical composition and anti-Streptococcus mutans activity by Nascimento, PFC, Alviano, WS, Nascimento, ALC, Santos, PO, Arrigoni-Blank, MF, De Jesus, RA, Azevedo, VG, Alviano, DS, Bolognese, AM, Trindade, RC

“…Objectives:  The aim of the present study was to evaluate the anti‐Streptococcus mutans activity of Hyptis pectinata essential oil, and present its promising…”
Get full text

New software for cervical vertebral geometry assessment and its relationship to skeletal maturation--a pilot study by Santiago, R C, Cunha, A R, Júnior, G C, Fernandes, N, Campos, M J S, Costa, L F M, Vitral, R W F, Bolognese, A M

“…In the present study, we developed new software for quantitative analysis of cervical vertebrae maturation, and we evaluated its applicability through a…”
Get full text

Antimicrobial activity of Croton cajucara Benth linalool-rich essential oil on artificial biofilms and planktonic microorganisms by Alviano, W. S., Mendonça-Filho, R. R., Alviano, D. S., Bizzo, H. R., Souto-Padrón, T., Rodrigues, M. L., Bolognese, A. M., Alviano, C. S., Souza, M. M. G.

“…We have previously demonstrated that a linalool‐rich essential oil from Croton cajucara Benth presents leishmanicidal activity. In the present study, we…”
Get full text

The influence of denosumab on one mineral densityand biochemical markers of bone remodeling: results of 6-year phase ii trial by Miller, P. D., Wagman, R.l B., Peacock, M, Lewiecki, E M, Bolognese, M. A., Weinstein, R. L., Ding, B, San Martin, J, McClung, M. R.

Get full text

Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials by Taggart, Hugh, Bolognese, Michael A, Lindsay, Robert, Ettinger, Mark P, Mulder, Henk, Josse, Robert G, Roberts, Anthony, Zippel, Hartmut, Adami, Silvano, Ernst, Teresa F, Stevens, Karen P

“…Risedronate sodium is a pyridinyl bisphosphonate effective for treatment and prevention of postmenopausal and glucocorticoid-induced osteoporosis. Some…”
Get more information

A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density by Orwoll, Eric, Teglbjærg, Christence S, Langdahl, Bente L, Chapurlat, Roland, Czerwinski, Edward, Kendler, David L, Reginster, Jean-Yves, Kivitz, Alan, Lewiecki, E. Michael, Miller, Paul D, Bolognese, Michael A, McClung, Michael R, Bone, Henry G, Ljunggren, Östen, Abrahamsen, Bo, Gruntmanis, Ugis, Yang, Yu-Ching, Wagman, Rachel B, Siddhanti, Suresh, Grauer, Andreas, Hall, Jesse W, Boonen, Steven

“…Context: Men with low bone mineral density (BMD) were treated with denosumab. Objective: Our objective was to investigate the effects of denosumab compared…”
Get full text

Epithelial alterations of secondary palate formation by Bittencourt, M A, Bolognese, A M

“…This study was undertaken to examine the normal and abnormal epithelial alterations of secondary palate in rats. Control and dexamethasone-treated embryos and…”
Get more information

A new concept for bisphosphonate therapy : a rationale for the development of monthly oral dosing of ibandronate by REGINSTER, Jean-Yves, FELSENBERG, Dieter, DUMONT, Etienne, BONVOISIN, Bernard, RECKER, Robert R, DELMAS, Pierre D, COOPER, Cyrus, STAKKESTAD, Jacob A, MILLER, Paul D, KENDLER, David L, ADAMI, Silvano, MCCLUNG, Michael R, BOLOGNESE, Michael A, CIVITELLI, Roberto

“…Oral daily and weekly bisphosphonates represent the current mainstay of treatment for postmenopausal osteoporosis (PMO). However, the inconvenience of frequent…”
Get full text

Ibandronate: the evolution of a once-a-month oral therapy for postmenopausal osteoporosis by Dempster, David W, Bolognese, Michael A

“…Bisphosphonates have been shown to be highly effective in preventing and treating postmenopausal osteoporosis (PMO) and the associated risk of fracture…”
Get more information

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial by Langdahl, Bente L, Libanati, Cesar, Crittenden, Daria B, Bolognese, Michael A, Brown, Jacques P, Daizadeh, Nadia S, Dokoupilova, Eva, Engelke, Klaus, Finkelstein, Joel S, Genant, Harry K, Goemaere, Stefan, Hyldstrup, Lars, Jodar-Gimeno, Esteban, Keaveny, Tony M, Kendler, David, Lakatos, Peter, Maddox, Judy, Malouf, Jorge, Massari, Fabio E, Molina, Jose Fernando, Ulla, Maria Rosa, Grauer, Andreas

“…Previous bisphosphonate treatment attenuates the bone-forming effect of teriparatide. We compared the effects of 12 months of romosozumab (AMG 785), a…”
Get full text

Bone morphology of the temporomandibular joint and its relation to dental occlusion by Matsumoto, M A, Bolognese, A M

“…The mandibular and temporal osseous components were analyzed in a sample of 30 dry skulls and their morphology was correlated with occlusal characteristics. In…”
Get more information

Efficacy and Safety of Monthly Oral Ibandronate In Postmenopausal Women With Osteopenia by McClung, Michael R, MD, Bolognese, MA, MD, Sedarati, F, MD, Recker, RR, MD, MACP, FACE, Miller, PD, MD

Get full text